effective inhibitors of fibronectin degradation although nm;-PI and ICI 200 355 were less effective. Recombinant SLPI was the most effective inhibitor when the cells were allowed to adhere to fibronectin before the addition of the inhibitors. Preincubation of rSLPI (0-1 ,umol/l) with the fibronectin plate resulted in almost total inhibition of fibronectin degradation (reduced to (SE 0 9)% of control).
Pretreating the fibronectin plate with 1 ,umol/l rSLPI, rm;-PI and ICI 200 355 followed by thorough washing before the addition of cells resulted in no inhibition of fibronectin degradation with rot,-PI and the ICI inhibitor, but rSLPI retained its inhibitory effect. This effect could be reduced by adding rSLPI in high pH buffer or 2 mol/l NaCl. Conclusions -It is postulated that rSLPI binds to fibronectin to form a protective layer which prevents its degradation by neutrophil elastase. It may prove to be the most useful therapeutic agent in the prevention of neutrophil mediated lung damage. (Thorax 1994; 49:567-572) Neutrophil elastase has been implicated in the pathogenesis of several chronic destructive lung diseases because of its ability to produce, in vitro and in vivo, many of the pathological features associated with these conditions. The enzyme is able to damage ciliated epithelium,' reduce ciliary beating,2 induce mucus gland hyperplasia3 and mucus secretion,4 all of which are features of chronic bronchitis. Furthermore, it can digest lung connective tissue 56 and this is thought to be responsible for the development of emphysema in animal models7 and man. 8 The exact mechanisms involved in the development of these diseases are unknown, although neutrophil recruitment and the release of elastase near the connective tissues and into the airways plays an important part. Neutrophils also secrete other proteinases such as cathepsin G and proteinase C which are able to degrade connective tissues. Previous studies have shown, however, that fibronectin solubilisation by neutrophils is largely caused by neutrophil elastase and not cathepsin G.9
Because of this central role of neutrophil elastase in the development of chronic lung disease there has been increasing interest in the development and potential therapeutic role of elastase inhibitors in the prevention of progressive lung damage.
Native and recombinant proteinase inhibitors have been used for preliminary studies and have been shown to inhibit elastase activity within the airways.'0'3 In addition, chemical inhibitors of neutrophil elastase have been developed which influence the development of chronic bronchitis and emphysema in animal models,'415 and therapeutic studies with these inhibitors are under way.
For any agent to be a realistic therapeutic option it must be capable of influencing the elastase load in the lung in a way which will alter the pathogenesis of the disease. The introduction of an effective inhibitor into the airways should reduce the elastase load on the epithelium thereby reducing bronchial damage. The inhibitor should interact irreversibly with neutrophil elastase, however, since reversible neutrophil elastase/inhibitor complexes may increase interstitial damage leading to emphysema. '5 16 Once in the lung the neutrophil becomes tightly adherent to connective tissues and can release neutrophil elastase into the microenvironment between the cell and substrate. Tissue destruction in this privileged site is remarkably resistant to the effects of proteinase inhibitors.6
Previous in vitro studies suggest that secretory leucoprotease inhibitor (SLPI) may be the most effective inhibitor as it is able to gain access to this privileged site, probably because of its relatively small molecular size (12 kDa), and it is therefore more effective at inhibiting proteolysis by adherent neutrophils.'718 Studies have shown that SLPI is associated with lung elastin and thus may protect it against digestion by neutrophil elastase. '9 The aim of the present study, therefore, was to assess the potential role of rSLPI in the cells/well) were dispensed into the wells and the plates incubated at 370C in a humidified atmosphere of 5% carbon dioxide/95% air for three hours. After incubation the supernatant was collected from the wells and the degraded fibronectin was assessed by counting with an LKB Multigamma II gamma counter. The 1251 counts in the supernatants of wells containing RPMI medium alone (blank) were deducted from those containing neutrophils. All experiments were performed in the absence (resting) and presence (stimulated cells) of 1 ,umol/l F-MetLeu-Phe (FMLP) and the result for each assay was determined from the mean value for three replicate wells.
The experiments were performed in three ways: (1) cells were preincubated with the inhibitors at varying concentrations for 30 minutes before being added together onto the fibronectin plate (preincubation); (2) cells and inhibitors were added to the fibronectin simultaneously (coincubation); and (3) the cells were allowed to adhere onto the fibronectin for 30 minutes followed by the inhibitors (adherent cells). The results obtained for the adherent cells were corrected for the 30 minutes before the addition of the inhibitors.
The effect of pretreating the fibronectin plates with the inhibitors before the addition of cells was also assessed. This was again performed in three ways: (1) the inhibitors at 0 1 pmol/l concentration in RPMI medium were added to the fibronectin and incubated at 37°C for 30 minutes before the addition of cells; (2) the inhibitors rSLPI, ra,-PI, and ICI 200 355 (0 1 ,umol/l and 1 0 pmol/l) were added to the fibronectin, incubated at 37°C for one hour, washed three times with RPMI medium, followed by addition of the neutrophils; and (3) rSLPI at 1 jmol/l concentration was dissolved in either RPMI medium of increasing pH from pH 7 4 to 12 5, or in 2 mol/I NaCl solution. The rSLPI in the varying buffers was pipetted onto the fibronectin plate and incubated for one hour at 37°C followed by three washes with RPMI medium at pH 7-4 to restore neutral pH. Following the washes and restoration of neutral pH the neutrophils were dispensed onto the fibronectin plates and the assay performed as usual. All experiment wells were repeated with three replicates and the value for each experiment taken as the mean. The effect of pH on the subsequent function of rSLPI was assessed by returning the solution to neutral pH and assessing the inhibitory activity as above. Figure 1 shows the relation between the molecular size of the natural proteinase inhibitors and efficiency at inhibiting fibronectin degradation by adherent neutrophils (n = 4 for each point).
In a further series of experiments the inhibitors (at 01 jImol/l) were added to the fibronectin plates for 30 minutes before the addition of the cells (pretreatment). is also an effective inhibitor of fibronectin degradation by neutrophils when preincubated with the cells before the assay, but when the cells had become adherent ra,-PI was less able to reduce fibronectin degradation.
The native form of a,-PI purified from human plasma was relatively ineffective at limiting fibronectin degradation by neutrophils when preincubated with them, and was even less effective when the neutrophils were allowed to become adherent. Although other workers6 have reported greater levels of inhibition using not,-PI in a similar assay system with up to 79 8 (SD 6 3)% inhibition of fibronectin degradation by adherent neutrophils compared with 33 1% inhibition in our assay, this can be explained by differences in the concentrations used (1 pmol/l in our assay v a calculated concentration of > 4 pmol/16). We cannot fully explain why the na,-PI was less effective than rao-PI at inhibiting fibronectin proteolysis as the concentrations used (0 01-1 ,umol/l) were based on functional activity. It may be partly related, however, to the smaller size of ra,-PI (due to lack of glycosylation). Alpha,-PI is thought to be excluded from the privileged site between neutrophils and fibronectin into which the neutrophil elastase is released and where proteolysis occurs. This concept is partly supported by the results with rSLPI. Recombinant SLPI has an even smaller molecular mass (12 000 Da) and may be able to gain access to the subcellular space of the adherent neutrophils more easily, thus explaining its comparable effectiveness at 1 gmol/l in limiting fibronectin degradation by both non-adherent and adherent cells. Other workers have also shown that rSLPI, unlike a,-PI, is able to protect connective tissue from degradation by adherent neutrophils.17 18 In particular, Rice and Weiss'7 reported that rSLPI was able to protect subjacent substrates from degradation by adherent neutrophils whereas plasma (containing a,-PI) was ineffective. When the neutrophils were prevented from becoming adherent, however, both inhibitors were equally effective. Using high concentrations of rSLPI (8 5 pmol/l) the authors were able to obtain 93% inhibition of fibronectin degradation and 88-5% inhibition of degradation of elastin by adherent neutrophils. The authors suggested that rSLPI may be exerting a protective effect by gaining access to proteolytic zones inaccessible to other inhibitors. Stolk et al,'8 in a more recent study, have shown that in a cell free system native SLPI and a,-PI were of equal potency at inhibiting neutrophil elastase, yet when cells were adherent to fibrinogen SLPI was more effective.
The results of these studies and those presented here suggest that the molecular size of the inhibitor is a determinant of its efficacy when neutrophils are tightly adherent to a substrate as illustrated in fig 1. The molecular size of the inhibitor is clearly not the only factor, however, as the small synthetic ICI inhibitor (685 Da) which should be most able to penetrate the cell substrate interface was less effective than even the larger protein inhibitors at limiting degradation of fibronectin by adherent neutrophils. These results suggest that the efficacy of rSLPI may not be simply a feature of its small molecular size.
Neutrophils are capable of releasing proteinases other than neutrophil elastase, such as cathepsin G and proteinase 3, into the subcellular space. The ICI inhibitor is a specific elastase inhibitor without any inhibitory effect on cathepsin G and proteinase 3. If these enzymes were contributing to the degradation of fibronectin the ICI inhibitor would therefore be expected to appear less effective than rSLPI and rac-PI. Previous studies characterising the degradation of fibronectin by neutrophils have found similar degradation products to those produced by pure neutrophil elastase. 9 In addition, specific cathepsin G chloromethylketones were unable to inhibit neutrophil mediated fibronectin degradation, suggesting that cathepsin G was not important in proteolysis. Recent studies have shown that SLPI does not have any inhibitory effect on proteinase 323 and, since SLPI inhibits fibronectin degradation by neutrophils, this provides further indirect support for the conclusion that fibronectin degradation by neutrophils is largely due to elastase. The ICI inhibitor would therefore be expected to be at least as effective as SLPI at inhibiting neutrophil mediated degradation of fibronectin if the size of the inhibitor is a critical factor in its efficacy.
The relative ineffectiveness of the ICI inhibitor suggests that factors other than size are also of major importance. This was confirmed by the experiments in which we showed that rSLPI was even more effective when added to the fibronectin plate before the cells, achieving > 96% inhibition, whereas there was no further increase in inhibition by ra,-PI or the ICI inhibitor (see results).
Previous studies have suggested that rSLPI can associate with elastin'9 and act as an inhibitor coat which prevents degradation by neutrophil elastase bound to the elastin. 24 In order to investigate the possibility that rSLPI was binding to the fibronectin we designed a further series of experiments in which fibronectin plates were incubated with 0 1 and 1 jmol/l solutions of rSLPI, ral-PI, or the ICI inhibitor for one hour followed by extensive washing. Following the washing the wells that had received roa,-PI and the ICI inhibitor were unable to inhibit fibronectin degradation by neutrophils, indicating that the inhibitor had been removed (fig 2) . The rSLPI wells still showed >90% inhibition at 1 gmol/l, however, suggesting that rSLPI had bound to the fibronectin. Recombinant SLPI is a highly cationic protein with a high isoelectric point (>9), so binding to connective tissue matrix such as fibronectin is likely to involve ionic bonds. To investigate this possibility we designed experiments to interfere with ionic bonding. RPMI medium of increasing pH containing 1 gmol/l rSLPI or rSLPI in 2 mol/l NaCl solution reduced the effectiveness of rSLPI, presumably by preventing binding to the fibronectin (fig 3) . The negative charges in the alkaline buffer would interfere with binding of rSLPI by neutralising its positive charges and thus inhibiting ionic bonding. A similar effect was seen with rSLPI in high salt solution, where there was also a reduction in the efficacy of rSLPI in the prevention of fibronectin degradation by neutrophils suggesting a reduction in rSLPI binding to fibronectin (by the negative chloride ions). To exclude the possibility that the high pH buffer was denaturing rSLPI and thereby reducing its inhibitory function we incubated the inhibitor for one hour in buffers of increasing pH as above. After restoration of neutral pH the activity of the inhibitor was titrated against pure neutrophil elastase as previously de However, a recent study has shown that native al-PI is able to bind in vitro to extracellular matrix composed of 51% glycoproteins, 37% collagen, and 12% elastin."5 The authors report that the a,-PI was not binding to the glycoproteins as removal of these from the matrix did not affect the binding to the rest of the matrix. It seems probable that the a,-PI was binding to the collagen (as previous studies have found SLPI but not a,-PI in association with elastin'9) thereby preventing its breakdown by neutrophil elastase. This work would be consistent with our data showing Llewellyn-JYones, Lomas, Stockley that rac-PI is unable to bind to the glycoprotein fibronectin.
Recombinant SLPI and rac-PI were both effective inhibitors of fibronectin digestion when preincubated with neutrophils (as in the circulation), but when cells are adherent to connective tissue (as in the interstitium) rSLPI was the best inhibitor, probably because of its ability to form a protective layer thus denying active neutrophil elastase access to connective tissues. Our data suggest an important role for rSLPI as a therapeutic agent in the protection of lung connective tissues. Further studies in vivo with this inhibitor are therefore required.
There has been much interest in augmentation therapy with a,-PI for subjects with ac -PI deficiency by systemic administration'0 and by inhalation in patients with cystic fibrosis." Our results show that rSLPI may be a more effective inhibitor in this situation and also in the prevention or treatment of smoking related emphysema and bronchitis in the absence of al-PI deficiency.
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